<DOC>
	<DOCNO>NCT00808288</DOCNO>
	<brief_summary>To assess effect safety PF-00610355 patient chronic obstructive lung disease ( COPD )</brief_summary>
	<brief_title>A Study To Investigate The Safety , Toleration And Efficacy PF00610355 In Chronic Obstructive Pulmonary Disease ( COPD ) Patients .</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Postbronchodilator FEV1/FVC ratio &lt; 0.7 postbronchodilator FEV1 5080 % . Diagnosis moderate COPD minimum 6 month . Stable disease least 1 month prior screen More 2 exacerbation COPD require treatment oral steroid precede year hospitalisation treatment COPD within 3 month screen twice precede year . History low respiratory tract infection significant disease instability month precede screening time screen randomisation .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>COPD Respiratory Long act beta agonist</keyword>
</DOC>